Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från CombiGene via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2018-12-14 13:25:44
The latest number of Nature (Vol. 564 Issue 7735, 13 December 2018) features CombiGene's operations, and the possibilities of using gene therapy to treat epilepsy, in a major article. Both CombiGene's scientific founder, Professor Merab Kokaia, and CEO Jan Nilsson, are quoted.
"CombiGene being featured in Nature like this makes me incredibly happy and proud. It is a clear sign that our research and development is beginning to attract international attention. With this fantastic conclusion to 2018, we will be going into 2019 even stronger and even more inspired," says CombiGene CEO Jan Nilsson.
Read the entire article here:
https://www.nature.com/magazine-assets/d41586-018-07644-y/d41586-018-07644-y.pdf